Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,924 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab, BYL719 drink suspension
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Conditions
Pain, Pancreatic Cancer
Interventions
morphine sulfate, Medtronic intrathecal pump
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Conditions
Brain Cancer, Pituitary Adenoma
Interventions
89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging, Blood and Urine samples
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Conditions
Refractory or Relapsed Solid Tumors, Lymphoma
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
0 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • The Bronx, New York
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
ziv-aflibercept, pharmacological study, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more
Conditions
Glioblastoma Multiforme, High-Grade Glioma
Interventions
Gliadel wafer, Temozolomide, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
Interventions
Mitoxantrone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Adult Brain Tumor, Lung Cancer, Radiation Toxicity
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 3 Interventional Results available

Preoperative Acetaminophen and Carbohydrate Loading

NCT03131713
Conditions
Non-melanoma Skin Cancer
Interventions
Acetaminophen
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma, Spinal Cord Compression
Interventions
Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Brain Tumors
Interventions
Massage Therapy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Breast Cancer, Colorectal Cancer, Pain
Interventions
Capecitabine, Celecoxib, Radiation Therapy, Placebo
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
Conditions
Lung Cancer
Interventions
CPAP
Device
Lead sponsor
Mark M. Fuster, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Conditions
Neurofibroma, Plexiform
Interventions
Imatinib Mesylate
Drug
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Shoulder Pain, Head and Neck Cancer
Interventions
Questionnaires
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome

NCT01425944
Conditions
Sturge-Weber Syndrome
Interventions
Not listed
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
1 Month and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
7
States / cities
Baltimore, Maryland • Detroit, Michigan • New York, New York + 4 more
Conditions
Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
Interventions
Armodafinil, placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Childhood CNS Tumor
Interventions
SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
Genetic · Radiation · Drug
Lead sponsor
SynerGene Therapeutics, Inc.
Industry
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Brain Metastases
Interventions
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, CD70 IHC assay
Biological · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic Brainstem Glioma, Diffuse Intrinsic Pontine Glioma, DIPG Brain Tumor, H3 K27M
Interventions
SIACI of cetuximab and bevacizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida